LT-IIb(T13I), a Non-Toxic Type II Heat-Labile Enterotoxin, Augments the Capacity of a Ricin Toxin Subunit Vaccine to Evoke Neutralizing Antibodies and Protective Immunity

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Greene, Christopher J ^a,b   Chadwick, Chrystal M ^c   Mandell, Lorrie M ^a,b   Hu, John C ^a,b   O'Hara, Joanne M ^c,d   Brey III, Robert N ^e   Mantis, Nicholas J ^c,d   Connell, Terry D ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c WADSWORTH CENTER   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e Soligenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; IMMUNOGLOBULIN G; IMMUNOLOGIC AGENT; IMMUNOLOGICAL ADJUVANT; LT IIB (T13I) TOXIN; LT IIB TOXIN; NEUTRALIZING ANTIBODY; RICIN ANTIBODY; RIVAX; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INTOXICATION; MOUSE; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; DRUG SYNERGISM; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLAMMATION; MICE; MICE, INBRED BALB C; SKIN; VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84881021363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069678     Document Type: Article

References (42)

1. Lord JM, Roberts LM, Robertus JD, (1994) Ricin: structure, mode of action, and some current applications. FASEB J 8: 201-208.
2. Audi J, Belson M, Patel M, Schier J, Osterloh J, (2005) Ricin poisoning: a comprehensive review. JAMA 294: 2342-2351.
3. Olsnes S, (2004) The history of ricin, abrin and related toxins. Toxicon 44: 361-370.
4. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES, (1993) Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 206: 227-234.
5. Lindstrom AL, Pennell CA, (2001) In vitro studies of ricin A-chain-induced vascular leak syndrome. Methods Mol Biol 166: 125-135.
6. Roche JK, Stone MK, Gross LK, Lindner M, Seaner R, et al. (2008) Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 88: 1178-1191.
7. Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, et al. (2010) Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents. Br J Pharmacol 161: 721-748.
8. Lemley PV, Amanatides P, Wright DC, (1994) Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 13: 417-421.
9. Furukawa-Stoffer TL, Mah DC, Cherwonogrodzky JW, Weselake RJ, (1999) A novel biological-based assay for the screening of neutralizing antibodies to ricin. Hybridoma 18: 505-511.
10. Wang Y, Guo L, Zhao K, Chen J, Feng J, et al. (2007) Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity. Biotechnol Lett 29: 1811-1816.
11. Hewetson JF, Rivera VR, Creasia DA, Lemley PV, Rippy MK, et al. (1993) Protection of mice from inhaled ricin by vaccination with ricin or by passive treatment with heterologous antibody. Vaccine 11: 743-746.
12. Hewetson JF, Rivera VR, Lemley PV, Pitt ML, Creasia DA, et al. (1995) A formalinized toxoid for protection of mice with inhaled ricin. Vaccine Res 4: 179-187.
13. Hewetson JFAA, Teters DR, Kotes JM, Washington E, Tamariello R, et al. (1996) Immune response and protection of rats and mice from ricin aerosol exposure after vaccination with deglycosylated ricin A chain (Abstract). Fundam Appl Toxicol 30 (Suppl):: 59.
14. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, et al. (2004) Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 17: 391-397.
15. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, et al. (2002) A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20: 3422-3427.
16. Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES, (2005) Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23: 4775-4784.
17. Smallshaw JE, Richardson JA, Vitetta ES, (2007) RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25: 7459-7469.
18. Smallshaw JE, Vitetta ES, (2010) A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity. Vaccine 28: 2428-2435.
19. Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES, (2010) Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine 28: 5315-5322.
20. Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, et al. (2006) A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A 103: 2268-2273.
21. Vitetta ES, Smallshaw JE, Schindler J, (2012) Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine. Clin Vaccine Immunol 19: 1697-1699.
22. Holmes RKJM, Connell TD (1995) Bacterial toxins and virulence factors in disease; Moss BIJ VM, Tu AT, editor. New York: Marcel Dekker, Inc.
23. Fishman PH, Moss J, Osborne JC Jr, (1978) Interaction of choleragen with the oligosaccharide of ganglioside GM1: evidence for multiple oligosaccharide binding sites. Biochemistry 17: 711-716.
24. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V, (1988) Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun 56: 1748-1753.
25. Martin M, Metzger DJ, Michalek SM, Connell TD, Russell MW, (2000) Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect Immun 68: 281-287.
26. Nawar HF, Arce S, Russell MW, Connell TD, (2005) Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect Immun 73: 1330-1342.
27. Liang S, Hosur KB, Nawar HF, Russell MW, Connell TD, et al. (2009) In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine 27: 4302-4308.
28. Nawar HF, Greene CJ, Lee CH, Mandell LM, Hajishengallis G, et al. (2011) LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb. Vaccine 29: 721-727.
29. Berenson CS, Nawar HF, Yohe HC, Castle SA, Ashline DJ, et al. (2010) Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I). Glycobiology 20: 41-54.
30. Nawar HF, Berenson CS, Hajishengallis G, Takematsu H, Mandell L, et al. (2010) Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I). Clin Vaccine Immunol 17: 969-978.
31. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4: e6999.
32. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V, (2010) Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 88: 424-430.
33. Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, et al. (2010) Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 130: 755-762.
34. Lenz A, Heine M, Schuler G, Romani N, (1993) Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 92: 2587-2596.
35. Mathias-Santos C, Rodrigues JF, Sbrogio-Almeida ME, Connell TD, Ferreira LC, (2011) Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration. Clin Vaccine Immunol 18: 1243-1251.
36. Neal LM, O'Hara J, Brey RN 3rd, Mantis NJ (2010) A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 78: 552-561.
37. O'Hara JM, Neal LM, McCarthy EA, Kasten-Jolly JA, Brey RN 3rd, et al (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28: 7035-7046.
38. Mastri M, Shah Z, McLaughlin T, Greene CJ, Baum L, et al. (2012) Activation of Toll-like receptor 3 (TLR3) amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol.
39. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, et al. (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167: 332-344.
40. Arce S, Nawar HF, Muehlinghaus G, Russell MW, Connell TD, (2007) In vitro induction of immunoglobulin A (IgA)- and IgM-secreting plasma blasts by cholera toxin depends on T-cell help and is mediated by CD154 up-regulation and inhibition of gamma interferon synthesis. Infect Immun 75: 1413-1423.
41. Vogelbruch M, Nuss B, Korner M, Kapp A, Kiehl P, et al. (2000) Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55: 883-887.
42. El S-C, Poelt P, Aberer W, Aberer E, (2009) Progressive circumscribed sclerosis-a novel side-effect of immunotherapy with aluminium-adsorbed allergen extracts. Allergy 64: 965-967.